For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220902:nRSB1140Ya&default-theme=true
RNS Number : 1140Y ReNeuron Group plc 02 September 2022
ReNeuron Group plc
("ReNeuron" or "the Group")
Share Purchase by a Director
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome
technologies, announces that Iain Ross, Chairman of the Company, has today
purchased 100,000 of the Company's ordinary shares of 1p each ("Ordinary
Shares").
Name Title Number of Ordinary Shares purchased Resulting beneficial interest in the Company's Ordinary Shares Percentage of Company's Total Voting Rights
Iain Ross Chairman 100,000 100,000 0.175%
ENDS
Enquiries:
ReNeuron www.reneuron.com/investors (http://www.reneuron.com/investors)
Iain Ross, Chairman Via Walbrook PR
Catherine Isted, Chief Executive Officer
Liberum Capital Limited (NOMAD and Joint Broker) +44 (0)20 3110 2000
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking)
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
(mailto:reneuron@walbrookpr.com)
Paul McManus +44 (0)7980 541 893
About ReNeuron
ReNeuron is a UK based leader in proprietary stem cell derived exosome
technologies, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.
ReNeuron's stem cell derived proprietary exosome technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Group has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.
The Group has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-license both of these programmes in other territories.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Iain Gladstone Ross
2 Reason for the notification
a) Position/status Chairman and Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Acquisition of ordinary shares
c) Price(s) and volume(s) Price(s) Volume(s)
25.85p 10,000
26.00p 30,000
27.70p 60,000
d) Aggregated information 100,000 ordinary shares at an average price of 27.005p at a total value of
£27,005
e) Date of the transaction 02 September 2022
f) Place of the transaction London Stock Exchange AIM Market
d)
Aggregated information
100,000 ordinary shares at an average price of 27.005p at a total value of
£27,005
e)
Date of the transaction
02 September 2022
f)
Place of the transaction
London Stock Exchange AIM Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFLFIIAIIFIIF